Revolution Medicines, Inc 10-Q for FY2026 Q3
Revolution Medicines, Inc. (RVMD)
10-Q
2026-11-04
For: 2026-09-30
View Original
Added on
November 04, 2026
About this 10-Q
Revolution Medicines, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Revolution Medicines began selling RASONQUE after FDA approval in August 2026, generating $197.6 million in net product revenue for the three and nine months ended September 30, 2026. Revenue included initial channel stocking. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $197.56M
- compared with $0 a year earlier
- Net loss
- $407.46M
- compared with a net loss of $305.21M a year earlier
- Diluted EPS
- -$1.90
- compared with -$1.61 a year earlier